Table 2. Assessment and management of anaphylaxis.
| Characteristic | n (%) |
|---|---|
| Clinical manifestations | |
| Cutaneous | 1,495 (84.0) |
| Respiratory | 971 (53.9) |
| Cardiovascular | 997 (55.4) |
| Gastrointestinal | 334 (18.5) |
| General | 378 (21.0) |
| Latency period (minute) | 181.6±1,210.1 |
| Time to arrival at hospital after developing symptoms (minute) | 279.8±1,065.8 |
| Management | |
| OPD/ED/Ward/ICU | 35.8/44.4/16.4/3.4 |
| Epinephrine use (Yes/No/Unknown) | 543 (30.1%)/879/384 |
| Total treatment period (days) | 9.5±37.8 |
| Positive on confirmatory testing | 415/536 (77.4) |
| Prescription of EpiPEN for secondary prevention | 126 (7.0) |
OPD, outpatient department; ED, Emergency Department; ICU, intensive care unit; EpiPEN, epinephrine auto-injector.